Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Artificial Intelligence Research of Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Xin Zhang, Master
- Phone Number: 13814066403
- Email: zhangxin@njglyy.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210093
- Recruiting
- Department of Radiology, the Affiliated Drum Tower Hospital of Nanjing University
-
Contact:
- Xin Zhang, Master
- Phone Number: 13814066403
- Email: zhangxin@njglyy.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergoing surgery in Nanjing DrumTower Hospital between 2010.01 and 2022.05 with post-surgery pathological diagnosis of WHO Grade II to IV Adult Diffuse Glioma.
- Available pre-surgery T1WI, T2WI, T1CE, FLARI and DWI MR sequences
- No pre-surgery anti-tumor therapy
Exclusion Criteria:
- Poor image quality
- Failed image preprocessing
- Unavailable pathology data
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Crossover
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Glioblastoma Group
Patients with the diagnosis of Glioblastoma based on 2021 WHO central nervous system tumor guideline.
|
Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.
The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test
|
|
Astrocytoma Group
Patients with the diagnosis of Astrocytoma based on 2021 WHO central nervous system tumor guideline.
|
Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.
The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test
|
|
Oligodendroglioma Group
Patients with the diagnosis of Oligodengroglioma based on 2021 WHO central nervous system tumor guideline.
|
Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.
The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tumor Grade
Time Frame: up to 2 weeks
|
Tumor Grade based on 2021 WHO central nervous system tumor guideline
|
up to 2 weeks
|
|
Tumor Histologic diagnosis
Time Frame: up to 2 weeks
|
Tumor histologic diagnosis based on 2021 WHO central nervous system tumor guideline
|
up to 2 weeks
|
|
Tumor genotype
Time Frame: up to 2 weeks
|
Tumor genotype based on 2021 WHO central nervous system tumor guideline
|
up to 2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022-LCYJ-MS-25
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.